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S U M M A R Y
The dosing of drugs in critically ill patients undergoing renal replacement therapy is based on limited
data. We report for the ﬁrst time single- and multiple-dose pharmacokinetics of ethambutol (EMB),
which is cleared renally to 80%, and rifampicin (RIF), which is cleared renally to <30%, in a patient
requiring both extracorporeal membrane oxygenation (ECMO) and renal replacement therapy. Extended
dialysis removed a considerable amount of both EMB and RIF, with a dialyser plasma clearance ranging
between 37 and 95 ml/min for EMB and between 39 and 53 ml/min for RIF. The EMB peak level (3 h after
a 2-h infusion) using a dose of 1000 mg/day on the ﬁrst day of treatment was 2.3 mg/l, which is in the low
therapeutic range (2–5 mg/l). Doubling the dose to 2000 mg/day resulted in peak levels slightly to
markedly above the recommended range. There was no detectable effect of the ECMO membrane on the
removal of both drugs. After an initial dose as for patients without renal impairment (15 mg/kg/day),
therapeutic drug monitoring should be used to guide EMB dosing in patients undergoing extended daily
dialysis.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Acute respiratory distress syndrome (ARDS) due to miliary
tuberculosis (TB) is associated with a 60% in-hospital mortality.1
Mortality increases to 100% if acute kidney injury ensues.
Ethambutol (EMB) and rifampicin (RIF) are an integral part of
combination therapy for TB, yet pharmacokinetic (PK) data are
scarce or even absent for critically ill patients receiving extended
daily dialysis, let alone those who additionally undergo extracor-
poreal membrane oxygenation (ECMO) therapy. We report for the
ﬁrst time the single- and multiple-dose pharmacokinetics of EMB
and RIF under combined extended dialysis and ECMO therapy in a
patient with ARDS due to infection with Mycobacterium
tuberculosis. Written consent was obtained for the publication of* Corresponding author. Tel.: +49 17627470868; fax: +49-511 532 4005.
E-mail address: ann-kathrin.strunk@gmx.net (A.-K. Strunk).
http://dx.doi.org/10.1016/j.ijid.2015.10.018
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).this study. Ethical approval to report this case was obtained from
the Institutional Review Board of the Medical School Hannover.
EMB (277.2 Daltons, protein binding 20–30%, volume of
distribution 1.6–3.2 l/kg) is primarily bacteriostatic at a minimum
inhibitory concentration (MIC) of 0.4–1.8 mg/ml, but can be
bactericidal at higher concentrations.2,3 First-line therapy of
new-onset TB includes a combination of isoniazid (INH), RIF,
pyrazinamide (PZA), and EMB for (at least) the ﬁrst 2 months, with
these showing additive and synergistic effects. Although having
less potent bactericidal activity against mycobacteria compared to
other agents, EMB decreases antibiotic resistance.4 In healthy
adults, the peak concentration of approximately 5 mg/l (at 15 mg/
kg body weight, orally) is reached after 2 h,3 and the elimination
half-life of EMB is about 4  2 h. In patients with impaired renal
function, an accumulation and prolongation of the half-life has been
observed, due to its preferential renal excretion as unchanged drug,
where it is even actively secreted via tubular cells.5 Additionally 15%
of EMB is secreted as inactive metabolites in the urine.3 EMB
pharmacokinetics in renal impairment is insufﬁciently explored. It isciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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clearance of 56 to 81 ml/min resulting in an elimination half-life of
approximately 2 h.3 Therefore, in patients with a creatinine clearance
<30 ml/min, the recommended dose is 15 mg/kg body weight three
times per week either 4–6 h before or directly after haemodialysis.4
RIF (822.9 Daltons, protein binding 80%, volume of distribution
0.64–0.66 l/kg), a bactericidal antibiotic drug, is usually added for
synergistic anti-tuberculostatic therapy and infused over 60 min.
RIF is reported not to be dialysed by continuous ambulatory
peritoneal dialysis (CAPD), HD, and haemodiaﬁltration (HDF). For
continuous veno-venous haemodialysis (CVVHD) its dialysability
is unknown. Less than 30% of RIF is excreted unchanged in the
urine and its half-life ranges from 2 to 5 h, with a peak
concentration of 11.8 mg/ml after 1.5 h in patients with normal
renal function and 5.5 mg/ml after 3.3 h in HD patients.6,7 In
patients with severe renal impairment (glomerular ﬁltration rate
(GFR) <10 ml/min), dosage adjustment of up to 50% is recom-
mended, which would result in a dosage of 300–600 mg daily in
two to four divided doses. The very same dosage is recommended
for patients undergoing renal replacement therapy.3
2. Case report
A 42-year-old male (weight 69 kg, height 178 cm) with a history
of intravenous drug abuse, levomethadone substitution, alcohol
abuse, and smoking (30 pack-years) was admitted to a local hospital
because of progressive dyspnoea, fever, and hypotension. HIV and
hepatitis C serology were negative. Due to chronic alcohol abuse, liver
function tests were elevated and liver synthesis was impaired. Severe
pneumonia prompted endotracheal intubation and mechanical
ventilation. Despite a fraction of inspired oxygen (FiO2) of 100%, an
adequate arterial oxygen concentration (PaO2) could not be achieved,
so the patient was transferred to the centre for veno-venous ECMO
treatment. PCR of bronchoalveolar lavage showed M. tuberculosis,
later conﬁrmed by culture analysis. As the mycobacteria were
resistant to streptomycin, treatment with RIF (600 mg/day), EMB
(1000 mg/day), PZA (2000 mg/day), and moxiﬂoxacin (400 mg/day)Figure 1. (A) Plasma concentrations of ethambutol (ﬁlled circles) and creatinine (ﬁlled sq
depicted by box size) on day 7 of treatment. (B) Dialyser plasma clearances and total amou
of four pharmacokinetic (PK).was started. Due to the underlying liver disease, INH was not used.
Meanwhile acute kidney injury ensued and extended daily dialysis
with a mean blood and dialysate ﬂow of 230 ml/min, mean duration
6.6 h, was initiated. For this treatment, the GENIUS dialysis system
was used (Fresenius Medical Care, Bad Homburg, Germany) with a
polysulfone high-ﬂux dialyser (F60S, surface area 1.3 m2; Fresenius
Medical Care). The technical details of the system are explained
elsewhere.8 One single-dose and three multiple-dose PK were
obtained for EMB, as well as two multiple-dose PK for RIF. Blood
samples were drawn at regular intervals before and after the
intravenous administration of the drugs, as well as throughout and
after the dialysis session. The moxiﬂoxacin PK had already been
studied previously by our group.9 The dialyser clearance (CLdial) was
calculated based on the plasma perfusion rate and extraction ratio (Ca
 Cv)/Ca, using the equation CLdial = Qe,  (Ca Cv)/Ca, where Qe is the
effective plasma perfusion rate of the dialyser (dialyser blood ﬂow
rate  (1  haematocrit)) and Ca and Cv are arterial and venous
dialyser plasma drug concentrations, respectively. Additionally, the
total amounts of the drugs were measured in the collected spent
dialysate. The samples were analyzed using liquid chromatography–
mass spectrometry in a certiﬁed laboratory (Labor Limbach,
Heidelberg, Germany).
The EMB peak level (3 h after a 2-h infusion) using a dose of
1000 mg/day on the ﬁrst day of treatment was 2.3 mg/l, which is at
the low end of the recommended therapeutic range of 2–5 mg/l.
Based on the therapeutic drug monitoring, the dose was doubled in
order to yield peak levels of EMB in the upper range of the
therapeutic window. However, peak concentrations varied sub-
stantially, ranging between 5.5 and 11 mg/l, with the latter being
well above the recommended range. Figure 1A depicts the EMB
plasma concentration on day 7 of EMB treatment before and during
extended dialysis. As shown in Figure 1B, extended dialysis with
the above-mentioned coordinates resulted in an average dialyser
clearance of EMB of 91 ml/min (range 51–131 ml/min) for whole
blood and 37–95 ml/min for plasma. RIF presented a dialyser
clearance between 53 and 77 ml/min for whole blood and between
39 and 53 ml/min for plasma. These results are comparable to datauares) in a patient with acute kidney injury undergoing extended dialysis (duration
nt in the spent dialysate of ethambutol, rifampicin, and creatinine based on the data
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Malone et al.6 calculated a dialyser clearance of 46 ml/min for EMB
and 40 ml/min for RIF. In our patient, 12–40% of the EMB dose and
5–23% of the administered RIF could be recovered in the spent
collected dialysate, which exceeds the amount reported by both
Lee et al. and Malone et al.6,10 There was no detectable effect of the
ECMO membrane on the removal of both drugs as we measured
pre- and post-ECMO ﬁlter levels of both drugs.
After an initial decline in inﬂammatory parameters, the
patient’s course was complicated by an inﬂuenza A infection, as
well as the growth of Aspergillus niger in the bronchoalveolar
lavage. One month after the initial presentation to a local hospital
the patient died due to multiorgan failure.
3. Discussion
These single- and multiple-dose pharmacokinetics of EMB and
RIF in a critically ill patient may suggest that extended dialysis
eliminates EMB effectively and to a larger extent than regular
intermittent haemodialysis in outpatients. Also RIF, previously
reported to be non-dialysable, could be found in the spent
dialysate. For TB treatment, the guidelines of the Centers for
Disease Control and Prevention (CDC) in conjunction with the
American Thoracic Society and the Infectious Diseases Society of
America recommend an EMB dose of 20 mg/kg body weight three
times per week for patients with renal dysfunction. For our patient,
this would have resulted in an EMB dose of 1400 mg three times a
week (i.e., 4200 mg EMB/week). It was decided to start with a
higher dose of EMB, 1000 mg/day (i.e., a dose of 7000 mg EMB/
week), as we performed daily extended dialysis. After ascertaining
the resulting peak levels of EMB to be in the lower part of the
recommended range, we doubled the EMB dose to avoid inefﬁcacy
and a potential development of resistance. A dosage of 2000 mg/
day (i.e., 14 000 mg EMB/week) led to peak concentrations slightly
to markedly above the recommended range, without any signs of
severe toxicity. Scoville et al. recently presented a case of EMB
optic neuropathy in a haemodialysis patient who received the
guideline-recommended dose of 1200 mg EMB three times a week,
which already led to toxicity.11 We conclude that after an initial
dose, as for patients without renal impairment (15 mg/kg/day),
therapeutic drug monitoring should be used to guide EMB dosing
in patients undergoing extended daily dialysis. Individualized
medicine requires this additional effort.Funding: This study was supported by internal funding.
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